Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.

@article{Knoll2001AntiagingC,
  title={Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.},
  author={Joseph Knoll},
  journal={CNS drug reviews},
  year={2001},
  volume={7 3},
  pages={
          317-45
        }
}
  • J. Knoll
  • Published 7 June 2006
  • Medicine
  • CNS drug reviews
Hundreds of millions of people now die over the age of 80 years primarily due to twentieth century progress in hygiene, chemotherapy, and immunology. With a longer average lifespan, the need to improve quality of life during the latter decades is more compelling. "Aging--The Epidemic of the New Millenium," a recent international conference (Monte Carlo, June 17-18, 2000), showed with peculiar clarity that a safe and efficient drug strategy to slow the age-related decay of brain performance is… 
The significance of selegiline/(−)-deprenyl after 50 years in research and therapy (1965–2015)
TLDR
The demonstration that the DEP analog (−)-1-phenyl-2-propylaminopentane devoid ofMAO inhibitory property, enhanced like DEP the activity of the catecholaminergic brain engine revealed that this effect is unrelated to the selective inhibition of MAO-B.
The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain
TLDR
Radioactivity was well absorbed and penetrated the brain, its elimination was fast and enterohepatic circulation was observed in rats, and more than 90% of the substance was recovered in the excreta during 72 hours.
The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
  • P. Gaszner, I. Miklya
  • Biology, Chemistry
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology
  • 2004
TLDR
The evaluation of the special pharmacological profile of the synthetic mesencephalic enhancer substance, especially the high potency and the unusual safety and tolerability of (-)-BPAP provide hope that this compound may in the future significantly improve the effectiveness of drug therapy in major depression and its combination with uptake inhibitors may substantially diminish the number of therapy resistant cases.
Acute and delayed effect of (−) deprenyl and (−) 1‐phenyl‐2‐propylaminopentane (PPAP) on the serotonin content of peritoneal cells (white blood cells and mast cells)
TLDR
The experiments emphasize the necessity of studying the prolonged effects of biologically active molecules, even if they are without acute effects, as serotonin is a modulator of the immune system and the influence on immune cells of the molecules studied can contribute to their enhancing effect.
...
...

References

SHOWING 1-10 OF 71 REFERENCES
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
TLDR
Early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.
(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
  • J. Knoll
  • Biology, Psychology
    Pharmacology & toxicology
  • 1998
TLDR
It may be supposed that a prophylactic low dose administration of a safe catecholaminergic activity enhancer substance during the postdevelopmental phase of life will slow the age-related decline of behavioral performances, delay natural death and decrease susceptibility to Parkinson's disease and Alzheimer's disease.
Deprenyl (selegiline): the history of its development and pharmacological action
  • J. Knoll
  • Biology, Chemistry
    Acta neurologica Scandinavica. Supplementum
  • 1983
TLDR
Deprenyl inhibits MAO‐B selectively in different animal species and in man and is able to block MAO-B activity in the brain selectively in vivo in four species with s.c. administration.
Preclinical Evaluation of l-Deprenyl: Lack of Amphetamine-Like Abuse Potential
TLDR
Evaluation of l-deprenyl for cocaine-like abuse liability is a relevant topic of research because the reinforcing effects of cocaine may be mediated by inhibition of dopamine reuptake, and l-Deprenyl, in addition to its MAO-B actions, also inhibits dopamine reptake.
The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant.
TLDR
1-phenyl-2-propylaminopentane facilitates learning and retention, is highly potent in antagonizing the tetrabenazine-induced depression in behavioral tests and is very effective in the forced swimming test.
(−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
TLDR
By changing the aromatic ring in PPAP the authors developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines, which significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of (−)BPAP.
...
...